[go: up one dir, main page]

MX2022003323A - Polinucleotidos dirigidos al sistema nervioso central. - Google Patents

Polinucleotidos dirigidos al sistema nervioso central.

Info

Publication number
MX2022003323A
MX2022003323A MX2022003323A MX2022003323A MX2022003323A MX 2022003323 A MX2022003323 A MX 2022003323A MX 2022003323 A MX2022003323 A MX 2022003323A MX 2022003323 A MX2022003323 A MX 2022003323A MX 2022003323 A MX2022003323 A MX 2022003323A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
targeting polynucleotides
system targeting
polynucleotides
Prior art date
Application number
MX2022003323A
Other languages
English (en)
Inventor
Dinah Wen-Yee Sah
Kartik Ramamoorthi
Yanqun Shu
Jinzhao Hou
Martin Goulet
Adrian Philip Kells
Pengcheng Zhou
Gregory Robert Stewart
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of MX2022003323A publication Critical patent/MX2022003323A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se relaciona con composiciones y métodos para la preparación, fabricación y uso terapéutico de polinucleótidos que codifican cargas para el tratamiento de trastornos del SNC.
MX2022003323A 2015-01-16 2017-07-17 Polinucleotidos dirigidos al sistema nervioso central. MX2022003323A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562104101P 2015-01-16 2015-01-16
US201562152185P 2015-04-24 2015-04-24
US201562152283P 2015-04-24 2015-04-24
US201562159888P 2015-05-11 2015-05-11
US201562159882P 2015-05-11 2015-05-11

Publications (1)

Publication Number Publication Date
MX2022003323A true MX2022003323A (es) 2022-04-18

Family

ID=56406481

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009336A MX2017009336A (es) 2015-01-16 2016-01-15 Polinucleótidos dirigidos al sistema nervioso central.
MX2022003323A MX2022003323A (es) 2015-01-16 2017-07-17 Polinucleotidos dirigidos al sistema nervioso central.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009336A MX2017009336A (es) 2015-01-16 2016-01-15 Polinucleótidos dirigidos al sistema nervioso central.

Country Status (7)

Country Link
US (3) US20180021364A1 (es)
EP (2) EP3245221A4 (es)
AU (2) AU2016206478A1 (es)
CA (1) CA2970730A1 (es)
HK (1) HK1246815A1 (es)
MX (2) MX2017009336A (es)
WO (1) WO2016115503A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077689A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11040113B2 (en) * 2015-03-23 2021-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
HK1258413A1 (zh) * 2015-10-29 2019-11-08 Voyager Therapeutics, Inc. 遞送中樞神經系統(cns)靶向多核苷酸
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics Inc composições e métodos de tratamento da doença de huntington
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
WO2018089527A1 (en) 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
SG11201909868YA (en) * 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US20200377887A1 (en) * 2017-09-22 2020-12-03 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3075656A1 (en) 2017-09-29 2019-04-04 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019076973A1 (en) * 2017-10-17 2019-04-25 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol VECTORS FOR THE TREATMENT OF FRIEDREICH ATAXIA
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ,インコーポレイテッド 抗体を回避するウイルスベクター
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
JP7528066B2 (ja) * 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
CN113302201A (zh) * 2018-11-21 2021-08-24 斯特里迪比奥公司 重组病毒载体和用于产生所述重组病毒载体的核酸
AU2020241888A1 (en) 2019-03-21 2021-09-30 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
WO2020223236A1 (en) * 2019-04-29 2020-11-05 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
JP2022536338A (ja) * 2019-06-10 2022-08-15 ホモロジー・メディシンズ・インコーポレイテッド Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法
JP2022548270A (ja) * 2019-09-13 2022-11-17 ラセルタ セラピューティクス, インコーポレイテッド フリードライヒ運動失調症の治療のための組成物及び方法
GB201913974D0 (en) * 2019-09-27 2019-11-13 King S College London Vector
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
IL293972A (en) * 2019-12-19 2022-08-01 Univ Pennsylvania Compositions for treating friedreich's ataxia
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
AR123288A1 (es) 2020-08-19 2022-11-16 Stridebio Inc Vectores de virus adenoasociados para el tratamiento del síndrome de rett
US20250235554A1 (en) 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
US20240081789A1 (en) * 2022-09-12 2024-03-14 Medtronic, Inc. Systems and methods for sampling a fluid
WO2024196794A2 (en) * 2023-03-17 2024-09-26 The Children's Hospital Of Philadelphia Compositions and methods for interneuron mediated delivery of cytotoxic agents to the brain

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US7931642B2 (en) 1998-09-18 2011-04-26 Codman Neuro Sciences Sarl Infusion pump comprising a computer for calculating the respective maximum permissible dosage
US6755814B2 (en) 1999-05-26 2004-06-29 Codman Neuro Sciences Sarl Implantable infusion pump with level measurement
US7366561B2 (en) 2000-04-07 2008-04-29 Medtronic, Inc. Robotic trajectory guide
WO2001083692A2 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6549803B1 (en) 2000-05-08 2003-04-15 Image-Guided Neurologics Inc. Method and apparatus for targeting material delivery to tissue
US6464662B1 (en) 2000-07-26 2002-10-15 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
US6572579B1 (en) 2000-09-13 2003-06-03 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
SG168422A1 (en) 2001-11-13 2011-02-28 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
JP4810062B2 (ja) 2001-12-17 2011-11-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア アデノ随伴ウイルス(aav)血清型8の配列
US7715902B2 (en) 2002-09-12 2010-05-11 Brainlab Ag Determining distribution for planning an infusion
US6691948B1 (en) 2003-04-10 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy High torque rocket nozzle
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US7848543B2 (en) 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
US7637897B2 (en) 2004-10-25 2009-12-29 Codman Neuro Sciences Sarl Implantable pump with integrated refill detection
US9101282B2 (en) 2005-09-22 2015-08-11 Brainlab Ag Brain tissue classification
EP1768041B1 (en) 2005-09-22 2016-04-13 Brainlab AG Brain tissue classification
US8240635B2 (en) 2005-10-26 2012-08-14 Codman Neuro Sciences Sárl Flow rate accuracy of a fluidic delivery system
US8141844B2 (en) 2005-10-26 2012-03-27 Codman NeuroSciences Sàrl Flow rate accuracy of a fluidic delivery system
US7905878B2 (en) 2005-10-31 2011-03-15 Codman & Shurtleff, Inc. Implantable pump with reservoir level detector
EP1788498A1 (en) 2005-11-21 2007-05-23 BrainLAB AG Apparatus for infusing substances
EP1956975A2 (en) 2005-11-29 2008-08-20 Surgi-Vision, Inc. Mri-guided localization and/or lead placement systems, related methods, devices and computer program products
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US7725272B2 (en) 2006-03-30 2010-05-25 Codman Neuro Sciences, Sarl Methods and devices for monitoring fluid of an implantable infusion pump
US20100030102A1 (en) 2006-05-15 2010-02-04 David Poston Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients
US7998128B2 (en) 2006-05-15 2011-08-16 Therataxis, LLC. Active delivery and flow redirection: novel devices and method of delivery of materials to patients
EP1992957B1 (en) 2007-05-16 2013-01-02 BrainLAB AG Method for estimating the physiological parameters defining the edema induced upon infusion of fluid from an intraparenchymally placed catheter
ES2557482T3 (es) 2007-05-17 2016-01-26 Medgenesis Therapeutix Inc. Catéter de entrega mejorada por convección con un miembro de rigidización eliminable
AU2008254328A1 (en) 2007-05-18 2008-11-27 The Johns Hopkins University A treatment simulator for brain diseases and method of use thereof
US8175677B2 (en) 2007-06-07 2012-05-08 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
EP2176283B1 (en) 2007-07-14 2016-11-02 University of Iowa Research Foundation Methods and compositions for treating brain diseases
US8548569B2 (en) 2007-09-24 2013-10-01 MRI Interventions, Inc. Head fixation assemblies for medical procedures
WO2009042130A2 (en) 2007-09-24 2009-04-02 Surgivision, Inc. Mri-guided medical interventional systems and methods
US8099150B2 (en) 2007-09-24 2012-01-17 MRI Interventions, Inc. MRI-compatible head fixation frame with cooperating head coil apparatus
WO2009067205A1 (en) 2007-11-21 2009-05-28 Surgi-Vision, Inc. Methods, systems and computer program products for positioning a guidance apparatus relative to a patient
US8545405B2 (en) 2008-04-23 2013-10-01 Therataxis, Llc Device, methods, and control for sonic guidance of molecules and other material utilizing time-reversal acoustics
US8083720B2 (en) 2008-05-13 2011-12-27 Solar Matthew S Device and method for delivering therapeutic agents to an area of the body
AR076634A1 (es) 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
WO2010096495A1 (en) 2009-02-18 2010-08-26 The Regents Of The University Of California Device, methods, and control for sonic guidance of molecules and other material utilizing time-reversal acoustics
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
JP2012529977A (ja) 2009-06-16 2012-11-29 エムアールアイ・インターヴェンションズ,インコーポレイテッド Mri誘導装置、及び準リアルタイムに該装置を追跡し、該装置の動的可視化を生成することができるmri誘導介入システム
US8679479B2 (en) 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
US8231563B2 (en) 2009-12-30 2012-07-31 Codman Neuro Sciences Sarl Electrokinetic actuator to titrate fluid flow
US10105485B2 (en) 2010-04-16 2018-10-23 MRI Interventions, Inc. MRI surgical systems including MRI-compatible surgical cannulae for transferring a substance to and/or from a patient
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
PL2598525T3 (pl) * 2010-07-28 2016-03-31 Roberto Testi Mutanty frataksyny
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
US9044492B2 (en) * 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
EP2678067A4 (en) 2011-02-24 2015-02-25 Mri Interventions Inc MRTI-CONTROLLED CATHETERS
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2013019830A2 (en) 2011-08-01 2013-02-07 Alcyone Lifesciences, Inc. Microfluidic drug delivery devices
US9192393B2 (en) 2012-05-31 2015-11-24 MRI Interventions, Inc. MRI compatible surgical drills and related methods
US10206693B2 (en) 2012-07-19 2019-02-19 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
US9498290B2 (en) 2012-07-19 2016-11-22 MRI Interventions, Inc. Surgical navigation devices and methods
US9031636B2 (en) 2012-07-19 2015-05-12 MRI Interventions, Inc. MRI-compatible head fixation apparatus
US9192446B2 (en) 2012-09-05 2015-11-24 MRI Interventions, Inc. Trajectory guide frame for MRI-guided surgeries
EP3738974A1 (en) 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Aav vectors targeted to oligodendrocytes
US20140243783A1 (en) 2012-10-06 2014-08-28 Raghu Raghavan Method of backflow reduction during material delivery through a needle into tissue
JP6430397B2 (ja) 2012-12-18 2018-11-28 アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. 送達システムにおける逆流を低減または防止するシステムおよび方法
US9066966B2 (en) * 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
US9572928B2 (en) 2013-03-13 2017-02-21 MRI Interventions, Inc. Substance delivery devices, systems and methods
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
US9498575B2 (en) 2013-03-14 2016-11-22 MRI Interventions, Inc. Substance delivery devices, systems and methods
US20140277310A1 (en) 2013-03-15 2014-09-18 Medtronic Ardian Luxembourg S.a.r.I. Catheters Having Tethered Neuromodulation Units and Associated Devices, Systems, and Methods
HK1220488A1 (zh) * 2013-03-15 2017-05-05 The Children's Hospital Of Philadelphia 含有填充者/填充物多核苷酸序列的载体及其使用方法
US9618590B2 (en) 2013-03-15 2017-04-11 MRI Interventions, Inc. Tip assembly for MRI-compatible medical devices and MRI-compatible medical devices incorporating same
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
WO2014189794A1 (en) 2013-05-18 2014-11-27 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods
WO2014204954A1 (en) 2013-06-17 2014-12-24 Alcyone Lifesciences, Inc. Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters
WO2015017609A2 (en) 2013-07-31 2015-02-05 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
EP3046500B1 (en) 2013-10-16 2020-08-26 ClearPoint Neuro, Inc. Surgical navigation system and related device
WO2015113027A2 (en) 2014-01-27 2015-07-30 Medtronic Ardian Luxembourg S.A.R.L. Catheters with enhanced flexibility and associated devices, systems, and methods
EP4253024B1 (en) 2014-01-27 2025-02-26 Medtronic Ireland Manufacturing Unlimited Company Neuromodulation catheters having jacketed neuromodulation elements and related devices
US10595744B2 (en) 2014-02-14 2020-03-24 MRI Interventions, Inc. Surgical tool-positioning devices and related methods
EP3119306A2 (en) 2014-03-20 2017-01-25 Medtronic Ardian Luxembourg S.à.r.l. Neuromodulation catheters and related devices, systems, and methods
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
KR20170096998A (ko) * 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
US11040113B2 (en) * 2015-03-23 2021-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia

Also Published As

Publication number Publication date
US20240285667A1 (en) 2024-08-29
EP3245221A4 (en) 2018-06-13
HK1246815A1 (zh) 2018-09-14
WO2016115503A1 (en) 2016-07-21
EP3245221A1 (en) 2017-11-22
US20180021364A1 (en) 2018-01-25
EP3632923A1 (en) 2020-04-08
AU2021204620A1 (en) 2021-07-29
CA2970730A1 (en) 2016-07-21
AU2016206478A1 (en) 2017-06-15
MX2017009336A (es) 2017-11-15
US20190365793A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2022003323A (es) Polinucleotidos dirigidos al sistema nervioso central.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
ZA202004557B (en) Modulatory polynucleotides
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2023010042A (es) Polinucleotidos moduladores.
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12019502002A1 (en) Combination theraphy
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
EP3694558A4 (en) IL-4 FUSION FORMULATIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12017501872A1 (en) Methods of treating diseases
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
TW201612183A (en) Diaryl macrocycles as modulators of protein kinases
GB201700502D0 (en) Treatment of tumours of the central nervous system
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll